Secondary Solid Malignancies After High-Grade Glioma Treatment in Pediatric Patients

Pediatr Hematol Oncol. 2015;32(7):467-73. doi: 10.3109/08880018.2015.1050615. Epub 2015 Aug 3.

Abstract

Due to the poor survival in high-grade glioma (HGG), secondary solid malignancies (SSM) following pediatric HGG are scarce. The authors present the experience from the HIT-HGG database in Germany, Austria, and Switzerland. Five out of 1228 pediatric HGG patients developed a SSM following a latency of 29-122 months from primary HGG diagnosis. In 4 patients, the SSM may be attributed to previous radiotherapy or a tumor predisposition syndrome, reflected by a markedly increased cumulative incidence rate of SSM in patients with tumor predisposition. Survival was devastating, since none of the patients survived beyond 18 months from SSM diagnosis.

Keywords: children; glioblastoma; high-grade glioma; secondary solid malignancies.

Publication types

  • Clinical Trial
  • Multicenter Study

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • Databases, Factual*
  • Disease-Free Survival
  • Female
  • Glioma* / mortality
  • Glioma* / therapy
  • Humans
  • Incidence
  • Infant
  • Infant, Newborn
  • Male
  • Neoplasms, Second Primary / mortality
  • Neoplasms, Second Primary / therapy
  • Survival Rate